Ligand Pharmaceuticals LGND Derivatives
Derivatives at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DerivativeAssetsNoncurrent.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's derivatives.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Ligand Pharmaceuticals's derivatives?
- Ligand Pharmaceuticals (LGND) reported derivatives of $13.53M in Q1 2026.
- How has Ligand Pharmaceuticals's derivatives changed year-over-year?
- Ligand Pharmaceuticals's derivatives decreased by 25.0% year-over-year, from $18.03M to $13.53M.
- What is the long-term trend for Ligand Pharmaceuticals's derivatives?
- Over 2 years (2023 to 2025), Ligand Pharmaceuticals's derivatives has grown at a 110.4% compound annual growth rate (CAGR), from $3.53M to $15.63M.